Is Day One Biopharmaceuticals, Inc. (DAWN) a Buy, Sell, or Hold?
Day One Biopharmaceuticals, Inc.
NASDAQ:DAWN
$21.53 USD
$0 (0.0%)
- Volume
- 0
- Average Volume
- 4.01M
- Market Capitalization
- $2.22B
- P/E Ratio
- -20.70
- Dividend Yield
- 0.00%
- Price Target
- $21.50
- Year High
- $21.53
- Year Low
- $5.64
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $8.02
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Jeremy Bender |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | DAWN |
| CUSIP | 23954D109 |
| CIK | 0001845337 |
| Web | https://dayonebio.com |
| Phone | 650 484 0899 |
| Currency | USD |
| Employees | 181 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.01 |
| Payout Ratio | 0.00 |
| Current Ratio | 8.02 |
| Quick Ratio | 7.91 |
| Cash Ratio | 3.26 |
Sales & Book Value
| Annual Sales | $158.18M |
| Price / Sales | 14.06 |
| Cash Flow | -1.04 |
| Price / Cash Flow | -20.68 |
| Price / Book | 5.05 |
Price Target and Rating
| Average Stock Price Forecast | $21.50 |
| High Stock Price Forecast | $21.50 |
| Low Stock Price Forecast | $21.50 |
| Forecast Upside/Downside | 0.14% |
| Consensus Rating | N/A |
| Rating Score(0-5) | 0 |
| Research Coverage | 12 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-1.04 |
| Trailing P/E Ratio | -20.70 |
| PEG Ratio | 0.40 |
| P/E Growth | 0.40 |
| Net Income | $-107.32M |
| Net Margin | -67.85% |
| Pretax Margin | -69.10% |
| Return on Equity | -23.43% |
| Return on Assets | -21.13% |
Financials Score
| AltmanZ Score | 18.80 |
| Piotroski Score | 3.00 |
| Working Capital | 424.58M |
| Total Assets | 507.83M |
| Ebit | -109.3M |
| Market Cap | 2.22B |
| Total Liabilities | 66.66M |
Poll Results
About Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Stock
Operating as a clinical-stage biopharmaceutical entity, Day One Biopharmaceuticals, Inc. is dedicated to discovering and commercializing precise therapeutic options for individuals battling genetically defined cancers. A key asset is DAY101, an orally administered, brain-permeable type II pan-rapidly accelerated fibrosarcoma kinase inhibitor, currently undergoing Phase II clinical trials for young patients experiencing recurrent or worsening low-grade glioma. Additionally, the company is advancing Pimasertib, an oral small molecule designed to inhibit mitogen-activated protein kinase kinases 1 and 2. Established in 2018, Day One Biopharmaceuticals, Inc. maintains its primary operations in South San Francisco, California. ...
Servier completes the acquisition of Day One Biopharmaceuticals
2026-04-23 08:30:00
Acquisition expands Servier's position in oncology with tovorafenib marketed as OJEMDATM in the U.S . in pediatric low-grade glioma.
Frequently Asked Questions
-
What is the current Day One Biopharmaceuticals, Inc. (DAWN) stock price?
-
Day One Biopharmaceuticals, Inc.(NASDAQ:DAWN) stock price is $21.53 in the last trading session. During the trading session, DAWN stock reached the peak price of $21.53 while $5.635 was the lowest point it dropped to. The percentage change in DAWN stock occurred in the recent session was 0.0% while the dollar amount for the price change in DAWN stock was $0.
-
DAWN's industry and sector of operation?
-
The NASDAQ listed DAWN is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of DAWN?
-
Lauren Merendino | Chief Commercial Officer
Jeremy Bender | Chief Executive Officer, President & Director
Heather Adkins Huet | Chief Scientific Officer
Joey Perrone | Senior Vice President of Finance & Investor Relations
John Stubenrauch | Chief Technology Officer -
How many employees does DAWN have?
-
Number of DAWN employees currently stands at 181. DAWN operates from 395 Oyster Point Boulevard, Brisbane, CA 94080, US.
-
Link for DAWN official website?
-
Official Website of DAWN is: https://dayonebio.com
-
How do I contact DAWN?
-
DAWN could be contacted at phone #650 484 0899 and can also be accessed through its website. DAWN operates from 395 Oyster Point Boulevard, Brisbane, CA 94080, US.
-
How many shares of DAWN are traded daily?
-
The average number of DAWN shares traded daily for last 3 months was 4.01M.
-
What is the market cap of DAWN currently?
-
The market value of DAWN currently stands at $2.22B with its latest stock price at $21.53